Trial Profile
Randomized multicenter phase II study evaluating two dosing schedules of TG4010 (MVA-MUC1-IL2) in patients with adenocarcinoma of the prostate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs TG 4010 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Nov 2006 Status change
- 11 Nov 2005 New trial record.